Literature DB >> 9537218

Do animal models have clinical value?

P J Schwartz1.   

Abstract

This article examines the efficacy of studying antiarrhythmic and antifibrillatory interventions using animal models. The importance of identifying appropriate animal models and comparing results from these studies to human clinical trials is discussed. Specific studies will be cited, the advantages/disadvantages of each design (i.e., internal control analysis factors, reproducibility of results, anesthetized vs conscious models) will be presented, and their ability or inability to predict clinical outcomes will be discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537218     DOI: 10.1016/s0002-9149(98)00148-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Optimizing dynamic interactions between a cardiac patch and inflammatory host cells.

Authors:  Donald O Freytes; Laura Santambrogio; Gordana Vunjak-Novakovic
Journal:  Cells Tissues Organs       Date:  2011-10-12       Impact factor: 2.481

2.  Patient-Specific Induced Pluripotent Stem Cell-Based Disease Model for Pathogenesis Studies and Clinical Pharmacotherapy.

Authors:  Yingxin Li; Karim Sallam; Peter J Schwartz; Joseph C Wu
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-06

3.  Effects of a novel amiodarone-like compound SAR114646A on the pig atrium and susceptibility to ventricular fibrillation in dogs and pigs.

Authors:  George E Billman; Heinz Gögelein; Hartmut Ruetten; Klaus J Wirth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-11       Impact factor: 3.000

4.  Dietary omega-3 fatty acids and susceptibility to ventricular fibrillation: lack of protection and a proarrhythmic effect.

Authors:  George E Billman; Cynthia A Carnes; Philip B Adamson; Emilio Vanoli; Peter J Schwartz
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-02-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.